This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Accelerate oligonucleotide and peptide products from early discovery to late-stage development & commercialization.

Addressing Complex Oligonucleotide Therapeutics and Approach Towards Endotoxin Removal

Share this article

Carter Holt, Process Development Supervisor at Axolabs, discusses the importance of removing endotoxins from biological solutions at the TIDES USA conference in San Diego, Calif. In this interview, Holt highlights the potential points of endotoxin introduction during the manufacturing process and discusses Axolabs’ approaches, including the use of charged filters, SEC chromatography, and ultrafiltration, for efficient endotoxin removal.

Share this article

Upcoming event

TIDES Asia: Oligonucleotide & Peptide Therapeutics Scientific Forum

19 - 21 Mar 2024, Kyoto, Japan

THE ONLY EVENT IN ASIA FOR OLIGO, PEPTIDE, mRNA, GENOME EDITING & DELIVERY EXPERTS TO EXCHANGE STRATEGIES TO ACCELERATE MOLECULES TO MARKET

Go to site